000 05736cam a2200757 i 4500
001 on1162002557
003 OCoLC
005 20201015090345.0
006 m o d
007 cr |||||||||||
008 120802s2012 nyu ob 001 0 eng
010 _a 2020677201
040 _aDLC
_beng
_erda
_cDLC
_dVLY
_dOCLCO
_dAZK
_dYDXCP
_dN$T
_dE7B
_dOCLCF
_dNLGGC
_dEBLCP
_dLOA
_dMERUC
_dAGLDB
_dICA
_dMOR
_dPIFAG
_dZCU
_dU3W
_dD6H
_dSTF
_dWRM
_dVTS
_dNRAMU
_dICG
_dVT2
_dWYU
_dDKC
_dAU@
_dM8D
_dK6U
_dUKCRE
019 _a828140625
_a923654270
_a961573436
_a962684398
_a966182436
_a988436558
_a992028910
_a1037927216
_a1038665338
_a1045509625
_a1055383791
_a1066451555
_a1081210814
_a1153513512
020 _a9781619423459
_q(ebook)
020 _a1619423456
020 _z9781619423435
020 _z161942343X
_q(hbk.)
029 1 _aAU@
_b000059385624
029 1 _aDEBBG
_bBV041049667
029 1 _aDEBBG
_bBV043961304
029 1 _aDEBBG
_bBV044087302
029 1 _aDEBSZ
_b481298959
029 1 _aNZ1
_b15025247
035 _a(OCoLC)1162002557
_z(OCoLC)828140625
_z(OCoLC)923654270
_z(OCoLC)961573436
_z(OCoLC)962684398
_z(OCoLC)966182436
_z(OCoLC)988436558
_z(OCoLC)992028910
_z(OCoLC)1037927216
_z(OCoLC)1038665338
_z(OCoLC)1045509625
_z(OCoLC)1055383791
_z(OCoLC)1066451555
_z(OCoLC)1081210814
_z(OCoLC)1153513512
050 0 0 _aRM405.5
060 4 _aWD 305
072 7 _aMED
_x044000
_2bisacsh
082 0 0 _a615.7/94
_223
049 _aMAIN
245 0 0 _aInfliximab :
_bpharmacology, uses and limitations /
_cAntonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors.
264 1 _aNew York :
_bNova Science Publishers, Incorporated,
_c[2012]
300 _a1 online resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _adata file
_2rda
380 _aBibliography
490 1 _aImmunology and immune system disorders
504 _aIncludes bibliographical references and index.
588 _aDescription based on print version record.
505 0 _a""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections""
505 8 _a""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohn�a�?s Disease ""; ""Fistulizing Crohn�a�?s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing ""
505 8 _a""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics""
505 8 _a""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity ""
546 _aEnglish.
590 _aeBooks on EBSCOhost
_bEBSCO eBook Subscription Academic Collection - Worldwide
650 0 _aInfliximab.
_0http://id.loc.gov/authorities/subjects/sh2002010978
650 0 _aInfliximab
_xTherapeutic use.
650 0 _aAnti-inflammatory agents.
_0http://id.loc.gov/authorities/subjects/sh85005615
650 2 _aAutoimmune Diseases
_xdrug therapy.
650 7 _aMEDICAL
_xImmunology.
_2bisacsh
650 7 _aAutoimmune diseases
_xChemotherapy.
_2fast
_0(OCoLC)fst00822665
650 7 _aInfliximab.
_2fast
_0(OCoLC)fst00972480
655 4 _aElectronic books.
700 1 _aMedrano Acevedo, Antonio D.
700 1 _aFajardo Gaitan, Montserrat.
776 0 8 _iPrint version:
_tInfliximab
_d[Hauppauge] New York : Nova Science Publishers, Inc., [2012]
_z9781619423435
_w(DLC) 2012418415
830 0 _aImmunology and immune system disorders.
_0http://id.loc.gov/authorities/names/n2010183470
856 4 0 _uhttps://libproxy.firstcity.edu.my:8443/login?url=http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=540914
938 _aProQuest Ebook Central
_bEBLB
_nEBL3017947
938 _aebrary
_bEBRY
_nebr10654918
938 _aEBSCOhost
_bEBSC
_n540914
938 _aYBP Library Services
_bYANK
_n7252252
994 _a92
_bMYFCU
999 _c42264
_d42264